Systemic administration of Hypocretin-1

Details Systemic administration of Hypocretin-1 Systemic administration of Hypocretin-1

2006-09-26

2006-09-26

Chernyshev, Olga N. (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C242S153000, C242S153000, C242S153000, C242S153000, C242S153000, C530S350000

Reexamination Certificate

active

07112566

ABSTRACT:
The invention provides compositions and methods for treatment of sleep disorders. Such methods entail administering to the patient a therapeutically effective dosage regime of an agonist of a hypocretin 1 (Hcrt-1) receptor to a peripheral tissue of the patient, and monitoring the condition of the patient responsive to the treatment, wherein the monitoring indicates a reduction in excessive daytime sleepiness (EDS) and an improvement in nighttime sleep consolidation and architecture. The methods are particularly useful for prophylactic and therapeutic treatment of one or more sleep disorders in a patient.

REFERENCES:
patent: 5196308 (1993-03-01), Nepon et al.
patent: 5541065 (1996-07-01), Erlich et al.
patent: 5565548 (1996-10-01), Neurath et al.
patent: 5908749 (1999-06-01), Mignot et al.
patent: 2005/0048538 (2005-03-01), Mignot et al.
patent: WO 01/08720 (2001-02-01), None
DSM-IV, fourth edition. 1994, APA, pp. 551-552.
Lin et al. Cell, 1999, 98, pp. 365-376.
Cadieux, R., et al., “Pharmacologic and psychotherapeutic issues in coexistent paranoid schizophrenia and narcolepsey:case report” J. Clin. Psychol. (1985) 46: 191-193.
Chemelli, R. M. et al., “Narcolepsey in orexin knockout mice: molecular genetics of sleep regulation,” Cell 98: 437-451 (1999).
Chen, et al., “Intracisternal administration of orexins increased blood pressure and heart rate urethane anesthetized rats,” Soc Neurosci Abst 25: 12 (1999).
Douglass, A., et al., “Florid refractory schizophrenias that turn out to be treatable variants of HLA-associated narcolepsy” J. Nerv. Ment. Dis. (1991) 179: 12-17.
Dube M. G., et al., “Food intake elicited by central administration of orexin/hypocretins: identification of hypothalamic sites of action,” Brain Res. 842: 473-477 (1999).
Hagan, J. J. et al., “Orexin A activates locus coeruleus cell firing and increases arousal in the rat,” Proc Natl Acad Sci U.S.A. 96: 10911-10916 (1999).
Kastin, A. J. and Akerstrom, V. (1999) “Orexin A but not orexein B rapidly enters brain from blood by simple diffusion,” J Pharmacol Exp Ther 289: 219-223.
Lin, L. et al., (1999) “The REM sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor gene” Cell 98: 365-376.
Mignot, E., et al., Sleep (1999) 22(3): 347-352.
Nishino, S. et al. (2000) “Hypocretin (orexin) deficiency in human narcolepsy” The Lancet 355: 39-40.
Takahashi, N. et al. (1999) “Stimulation of gastric acid secretion by centrally administered orexin- A in conscious rats” Biochem Biophys Res Commun 254: 623-627.
Peyron et al., “A mutation in case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains,”Nature Medicine6:991-997 (2000).
John, et al., Hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogsSleep, vol. 23, DRAFT Abstract, available on meeting webpage for all meeting authors to review, Mar. 6-9, 2000.
John, et al., Hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogsSleep, vol. 23, Abstract Supplement 2, A 11-12, Apr. 15, 2000.
Xi et al, “Microinjection of orxin-A (hypocretin-1) into the laterodorsal tegmental nucleus of the cat: effects on sleep and waking states,”Society for Neuroscience Abstracts26:15 (2000).
Fujiki, Nobuhiro et al., “Effects of IV And ICV Hypocretin-1 (Orexin A) In Hypocretin Receptor-2 Gene Mutated Narcoleptic Dogs And IV Hypocretin-1 Replacement Therapy In A Hypocretin-Ligand-Deficient Narcoleptic Dog,” Sleep, vol. 26, No. 8, pp. 953-959, 2003.
Hanson, Leah R. et al., “Intranasal Administration Of Hypocretin 1 (Orexin A) Bypasses The Blood-Brain Barrier & Targets The Brain: A New Strategy For The Treatment Of Narcolepsy,” Drug Delivery Technology, vol. 4, No. 4, 10 pages, May 2004.

Affiliated with

Also associated with

Rating

Systemic administration of Hypocretin-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Systemic administration of Hypocretin-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systemic administration of Hypocretin-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3527764